Next steps with RTOG 0126 trial genomic testing findings in prostate cancer

“I think that [these findings] definitely [warrant] standard of care radiation and hormone therapy for these patients or other forms of radical therapy,” says Daniel E. Spratt, MD.

In this video, Daniel E. Spratt, MD, discusses further research and application associated with the findings of the study, “Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Spratt is a Vincent K. Smith professor and chair at Case Western Reserve University School of Medicine and chair of radiation oncology at University Hospitals Cleveland Medical Center in Cleveland, Ohio.